High-throughput phenotypic screening is a cornerstone of drug development and the main technical approach for stem cell research.However,simultaneous detection of activated core factors responsible for cell fate deter...High-throughput phenotypic screening is a cornerstone of drug development and the main technical approach for stem cell research.However,simultaneous detection of activated core factors responsible for cell fate determination and accurate assessment of directional cell transition are difficult using conventional screening methods that focus on changes in only a few biomarkers.The PHDs-seq(Probe Hybridization based Drug screening by sequencing)platform was developed to evaluate compound function based on their transcriptional effects in a wide range of signature biomarkers.In this proof-of-concept demonstration,several sets of markers related to cell fate determination were profiled in adipocyte reprogramming from dermal fibroblasts.After validating the accuracy,sensitivity and reproducibility of PHDs-seq data in molecular and cellular assays,a panel of 128 signalling-related compounds was screened for the ability to induce reprogramming of keloid fibroblasts(KF)into adipocytes.Notably,the potent ATP-competitive VEGFR/PDGFR inhibitor compound,ABT869,was found to promote the transition from fibroblasts to adipocytes.This study highlights the power and accuracy of the PHDs-seq platform for high-throughput drug screening in stem cell research,and supports its use in basic explorations of the molecular mechanisms underlying disease development.展开更多
基金supported by the National Key Research and Development Program of China(2019YFA0110000,2018YFA0800504)the National Natural Science Foundation of China(31922020)+1 种基金Clinical Medicine Plus X-Young Scholars Project from Peking University(PKU2020LCXQ002)fundings provided by Plastech Pharmaceutical Technology Co.,LTD.
文摘High-throughput phenotypic screening is a cornerstone of drug development and the main technical approach for stem cell research.However,simultaneous detection of activated core factors responsible for cell fate determination and accurate assessment of directional cell transition are difficult using conventional screening methods that focus on changes in only a few biomarkers.The PHDs-seq(Probe Hybridization based Drug screening by sequencing)platform was developed to evaluate compound function based on their transcriptional effects in a wide range of signature biomarkers.In this proof-of-concept demonstration,several sets of markers related to cell fate determination were profiled in adipocyte reprogramming from dermal fibroblasts.After validating the accuracy,sensitivity and reproducibility of PHDs-seq data in molecular and cellular assays,a panel of 128 signalling-related compounds was screened for the ability to induce reprogramming of keloid fibroblasts(KF)into adipocytes.Notably,the potent ATP-competitive VEGFR/PDGFR inhibitor compound,ABT869,was found to promote the transition from fibroblasts to adipocytes.This study highlights the power and accuracy of the PHDs-seq platform for high-throughput drug screening in stem cell research,and supports its use in basic explorations of the molecular mechanisms underlying disease development.
